Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.

Abstract	We report a case of refractory peripheral T-cell lymphoma (PTCL) successfully treated with a combination of fludarabine and cyclophosphamide (FLU/CY). A 68-year-old man with concurrent PTCL and diffuse large B-cell lymphoma was treated effectively with 3-course CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy, but PTCL relapse occurred and was resistant to ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) therapy. FLU/CY therapy led to complete remission, which was maintained for almost 14 months after a single course. We concluded that a FLU/CY regimen may be useful for attaining long-term remission in patients with refractory relapsed PTCL and should therefore be considered a valuable treatment choice.
Authors	Masaki Yamaguchi, Takeharu Kotani, Yoshihisa Nakamura, Mikio Ueda
Journal	International journal of hematology (Int J Hematol) Vol. 83 Issue 5 Pg. 450-3 (Jun 2006) ISSN: 0925-5710 [Print] Japan
PMID	16787878 (Publication Type: Case Reports, Journal Article)
Chemical References	Cytarabine Vincristine Etoposide Doxorubicin Cyclophosphamide Vidarabine fludarabine Cisplatin Prednisone Methylprednisolone
Topics	Aged Antineoplastic Combined Chemotherapy Protocols (administration & dosage) Cisplatin (administration & dosage) Cyclophosphamide (administration & dosage) Cytarabine (administration & dosage) Doxorubicin (administration & dosage) Drug Resistance, Neoplasm (drug effects) Etoposide (administration & dosage) Humans Lymphoma, B-Cell (drug therapy, pathology) Lymphoma, Large B-Cell, Diffuse (drug therapy, pathology) Lymphoma, T-Cell, Peripheral (drug therapy, pathology) Male Methylprednisolone (administration & dosage) Neoplasms, Second Primary (drug therapy, pathology) Prednisone (administration & dosage) Recurrence Remission Induction Time Factors Vidarabine (administration & dosage, analogs & derivatives) Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!